Humana (NYSE:HUM) Price Target Lowered to $273.00 at Barclays

Humana (NYSE:HUM) had its price target lowered by Barclays from $322.00 to $273.00 in a research report report published on Monday,Benzinga reports. Barclays currently has an equal weight rating on the insurance provider’s stock.

Several other research analysts have also issued reports on the company. Truist Financial lowered their target price on Humana from $325.00 to $305.00 and set a “hold” rating for the company in a research report on Monday, May 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. JPMorgan Chase & Co. cut their price target on Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a research note on Tuesday, February 18th. Oppenheimer lifted their price target on Humana from $300.00 to $310.00 and gave the company an “outperform” rating in a research note on Thursday, May 1st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Sixteen equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus target price of $284.48.

Humana Trading Down 0.9%

Shares of NYSE:HUM opened at $230.96 on Monday. The company has a market capitalization of $27.87 billion, a P/E ratio of 23.21, a P/E/G ratio of 2.05 and a beta of 0.49. Humana has a 1 year low of $212.45 and a 1 year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The business’s 50 day simple moving average is $256.32 and its 200 day simple moving average is $266.21.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. During the same quarter last year, the business posted $7.23 EPS. The company’s revenue was up 8.4% compared to the same quarter last year. On average, research analysts anticipate that Humana will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.53%. Humana’s dividend payout ratio (DPR) is presently 25.04%.

Hedge Funds Weigh In On Humana

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Humana by 8.9% during the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider’s stock valued at $3,697,222,000 after acquiring an additional 1,143,662 shares in the last quarter. Dodge & Cox increased its position in shares of Humana by 5.5% during the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider’s stock valued at $2,845,830,000 after acquiring an additional 557,175 shares in the last quarter. Pzena Investment Management LLC increased its position in shares of Humana by 6.1% during the first quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider’s stock valued at $1,013,133,000 after acquiring an additional 219,541 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Humana by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider’s stock valued at $729,658,000 after acquiring an additional 63,562 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Humana by 29.8% in the fourth quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider’s stock worth $608,348,000 after purchasing an additional 550,692 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.